Description
pAAVr2.15
Adeno-associated Viral Vector (AAV) capsid r2.15 in AAV2Rep expression construct.
Applied a directed evolution approach involving the generation of large mutant capsid libraries and selection of AAV2 variants with enhanced properties. High-throughput selection processes were designed to isolate mutants within the library with altered affinities for heparin or the ability to evade antibody neutralization and deliver genes more efficiently than wild-type capsid in the presence of anti-AAV serum.The neutralizing antibody titer of r2.15 was 96-fold improved compared to wild type.
DOI: 10.1038/nbt1182.
The r2.15 mutant, which had a neutralizing titer 96-fold better than wild type, has two mutations absent from any other mutant. T567S is a conservative mutation that lies in a minor epitope associated with the A20 monoclonal antibody, whereas N587I lies in the heparin-binding domain, whose disruption has been shown to confer limited escape from neutralization by serum from certain human patients
MAADGYLPDWLEDTLSEGIRQWWKLKPGPPPPKPAERHKDDSRGLVLPGYKYLGPFNGLDKGEPVNEADAAALEHDKA
YDRQLDSGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRVLEPLGLVEEPVKTAPGKKRPVEHSPVEPDSSS
GTGKAGQQPARKRLNFGQTGDADSVPDPQPLGQPPAAPSGLGTNTMATGSGAPMADNNEGADGVGNSSGNWHCDST
WMGDRVITTSTRTWALPTYNNHLYKQISSQSGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRL
NFKLFNIQVKEVTQNDGTTTIANNLTSTVQVFTDSEYQLPYVLGSAHQGCLPPFPADVFMVPQYGYLTLNNGSQAVGRSS
FYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDRLMNPLIDQYLYYLSRTNTPSGTTTQSRLQFSQAGASDIRD
QSRNWLPGPCYRQQRVSKTSADNNNSEYSWTGATKYHLNGRDSLVNPGPAMASHKDDEEKFFPQSGVLIFGKQGSEKT
NVDIEKVMITDEEEIRSTNPVATEQYGSVSTNLQRGIRQAATADVNTQGVLPGMVWQDRDVYLQGPIWAKIPHTDGHFHPS
PLMGGFGLKHPPPQILIKNTPVPANPSTTFSAAKFASFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYNKSVNVDFT
VDTNGVYSEPRPIGTRYLTRNL*
$1,500.00 – $3,000.00